Features:
-Excellentgenedeliveryefficiencyinmostcelltypesincludingdividingandnon-dividingorprimarycells.
-MultipleSEROtypes(AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-8,AAV-9,AAV-DJ/8andAAV-DJ).
-Persistenttransgeneexpression.
-Induceefficientgenesilencing.
LargeshRNA/miRNA/gRNAAAVcisvectorinventoryforconstructingAAVcisplasmidwithaspecificpromoterandreporter:
| ForConventionalshRNA/miRNA/TuDrAAVProduction | |||||
Single-promotershRNA/miRNAAAVcisvector | Dual-promotershRNA/miRNArAAVcisvector | ||||
Promoterless |
| Promoterless | CMV | eGFP | |
| ForCRISPR/Cas9rAAVProduction | |||||
Single-promoterCRISPR/Cas9AAVcisvector | Dual-promoterCRISPR/Cas9AAVcisvector | ||||
Promoterless | Empty | Cas9 hCas9 SpCas9 hSpCas9 SaCas9 AsCpf1 hAsCpf1 ftCas9 st1Cas9 cjCas9 cdCas9 ciCas9 ncCas9 st3Cas9 nmCas9 mgCas9 nsCas9 | Promoterless | CMV | Cas9 |
ServiceDescription:
1.SynthesizeandcloneshRNAintoAAVcisvectors.
2.MediumscaletransfectionofAAV·HT™293cellinto1xcellstack.
3.HarvestrAAVparticlefollowedbypurificationviaadvanced2xCsClultra-centrifugationtoobtainclinicaltrialgradeofrAAVvector.
4.rAAVtitrationviaqPCR.
rAAVSerotypesWeOffer:
AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-7,AAV-8,AAV-9,AAV-PHP.B,AAV-DJ/8andAAV-DJ.
RequiredMaterials:NCBIaccession#,targetsequence,validatedsiRNAorvalidatedshRNAsequence;miRNAaccession#,pre-miRNA,maturemiRNAorTuD(toughdecoy)miRNA.
TurnaroundTime:3~4weeks.
Deliverables:>0.2mLsuperpurifiedinvivogradeofrAAVvectorat>1E+13VG/mL*.
Weofferdiscountfornewcustomer,pleaserequestaquotewithustoday.
WealsooffertruncatedcustomshRNA/miRNAAAVservice,pleaserequestaquotewithustoday.
Figure1.AcomparisonofpurityandinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedandsuperinfectious(closetoclinicaltrialgrade)rAAVvectorpreparedviaouradvanceddoubleCsClultra-centrifugationapproach.
A.rAAVvectors(total1E+9VGperlane) fromdifferentsourceswereresolvedonSDS-PAGEfollowedbysilverstaining. Lane1:GMPmanufacturedrAAVvectorfromCHOP;Lane2:rAAVpreparedviaouradvanced2xCsClultra-centrifugationapproach;Lane3:rAAVfromVectorCoreofBCM;Lane4:rAAVfromourcompetitor"V";Lane5:rAAVfromourcompetitor"C";Lane6:ProteinMarker.
B.SuperinfectiousrAAVvectorpreparedviaadvanceddoubleCsClultra-centrifugation. Leftpanel:rAAV9-GFP(total5E+9VG)fromourcompetitor"V"injectedtomouseeye;Rightpanel:rAAV-9-GFP(total5E+9VG)purifiedviaadvanced2xCsClultra-centrifugationinjectedtomouseeye. 
Figure2.AcomparisonofinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedrAAVpreparedviaadvanceddoubleCsClultra-centrifugationapproachissuperinfectious.
rAAV1-GFP(total2E+9VG)fromdifferentsourceswereinjectedtomousemuscletissue. TheGFPfluorescencewasvisualized3weekspostinjection. A.rAAV1-GFPfromourcompetitor"V";B.rAAV1-GFPfromourpre-maderAAVsstockpurifiedviaadvanceddoubleCsClultra-centrifugation. C.QuantificationdatashowedthatoursuperpurifiedrAAV(bar2)is~9timesmoreinfectiousthanthat(bar1)preparedviaconventionalCsClultra-centrifugation.
*Finalviralyieldmaydependonthenatureoftransgene.
